knowledge -WSS

knowledge

author：explore 2025-09-06 04:15:37 - browse：4

On Tuesday, Google DeepMind and Isomorphic Labs announced a significant progress update on the next iteration of AlphaFold, the deep learning model that in 2020 cracked the problem of predicting a protein’s structure from its amino acid sequence, leapfrogging other approaches in computational biology.

Now, the companies say they have developed the model to predict not just standalone protein structures, but what proteins look like in combination with several classes of molecules, including small molecules and nucleic acids — capabilities that are key for drug development.

“We really needed to make progress on protein-ligand binding and co-folding of ligands with proteins in order to help us design more effective drugs,” said Demis Hassabis, CEO of both DeepMind and Isomorphic Labs, which spun out in 2021 with the goal of applying deep learning approaches to drug discovery. The updated model can also predict protein structures after they’ve been modified. “Basically the new AlphaFold can cope with all of these different things, which is pretty amazing.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Bristol 'take

focus

knowledge

WSS

FDA approves Sage Therapeutics’ rapid

It costs an awful lot of money to give away a kidney

2 officers injured in shooting in Orlando, police say

It costs an awful lot of money to give away a kidney

Heart disease in astronauts blamed on cosmic radiation

Stroke deaths set to near 10 million globally by 2050

leisure time

knowledge

focus

Psychedelics group wrestles with new pharma identity

What to expect at HLTH 2023, the health care industry conference

Anesthesiologist group: stop taking Ozempic before surgery

Alnylam reports growth in sales of rare disease treatments

The cancer drug shortage isn’t new — and neither are the solutions

Alnylam reports growth in sales of rare disease treatments

Dobbs anniversary: the lost opportunity of abortion as health care

Phenylephrine and the overlooked value of the placebo effect

Cancer drug shortages should be causing more outrage

What to expect at HLTH 2023, the health care industry conference

focus

When waiting feels immoral: Empathy in the emergency department

FDA authorizes Novavax’s updated Covid

Sana to lay off nearly a third of staff, de

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Group behind ProMed defends move to subscription

knowledge

focus

knowledge

Wikipedia